DCOY

Lead pan-coronavirus program expected to file CTA/IND in 2H 2027 Optimized lead candidate shows potential for once-weekly dosing in preclinical studies Cash on balance sheet of $8.1 million at September 30, 2026 CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs) to target major respiratory and high-consequence viral threats, today provided a business update for the third quarter ended September 30, 2026.

CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York

Once-Weekly Intranasal Potential : Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue. Addressing Endemic Coronaviruses : DCOY-CoV is designed to protect against endemic human coronaviruses (OC43, 229E, NL63, HKU1, and SARS-CoV-2), in people at high risk of serious illness including the more than 20 million high-risk immunocompromised and 15 million COPD patients in the U.S. and Europe.

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the Series B Milestone Warrants to purchase shares of the Company's common stock, for a total of 1,184,434 warrants (the "Existing Warrants").

Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program along the U.S. Food and Drug Administration (FDA) Animal Rule pathway for expedited regulatory approval.

Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New York Cambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9 and 10, 2026 in New York City. Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference.

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform.

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute.

CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia Gauthier, MBA, LL.B.

CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced the nomination of Patricia Gauthier, MBA, LL.B.